Mogamulizumab-kpkc and Lenalidomide combination to Tce;; leuemia/ lumphoma – pro
Mogamulizumab (MOG) is an antibody targeting the CCR4 receptor, authorized for relapsed or refractory peripheral T-cell (PTCL) and cutaneous T-cell lymphomas (CTCL). Its adoption in guidelines and endorsement by FDA and EMA established it as a systemic treatment, especially for advanced disease stages due to its comparatively lower toxicity. 5 clinical trials in which lenalidomide monotherapy was investigated to treat TCL, including cutaneous TCL and adult T-cell lymphoma/leukemia. Overall response rate was between 10 % and 43%, with prolonged response in a significant proportion of cases and manageable toxicity. However, I did not find trials fo the two drugs together; as such, it should be considered E/I and not medically necessary.
Srinivasan published a retrospective analyses, but such data is tno sufficient to establish medical necessity.
Fernández-Guarino M, Ortiz P, Gallardo F, Llamas-Velasco M. Clinical and Real-World Effectiveness of Mogamulizumab: A Narrative Review. Int J Mol Sci. 2024 Feb 12;25(4):2203. doi: 10.3390/ijms25042203. PMID: 38396877; PMCID: PMC10889597
Cencini E, Fabbri A, Mecacci B, Bocchia M. Role of lenalidomide in the treatment of peripheral T-cell non-Hodgkin lymphomas. World J Clin Oncol. 2021 Oct 24;12(10):882-896. doi: 10.5306/wjco.v12.i10.882. PMID: 34733611; PMCID: PMC8546656..
Maya D. Srinivasan,et al, Mogamulizumab Combinations in Patients with Relapsing/Refractory Adult T-Cell Leukemia/Lymphoma (r/r ATLL). Blood (2024) 144 (Supplement 1): 6405. .
Jordan Pilimgton et also, Mogamulizumab in combination improves clinical outcomes in relapsed and refractory Sézary syndrome. Front. Hematol., 13 May 2025 Sec. Blood Cancer
Volume 4 – 2025 | https://doi.org/10.3389/frhem.2025.1557641